McKesson Corporation reports developments tied to its role as a diversified healthcare services company and major pharmaceutical distributor. Company news commonly covers fiscal results and guidance, dividend declarations, capital allocation, share repurchase activity, and updates across core distribution, oncology and multispecialty, biopharma services, pharmacy technology, and medical-surgical product categories.
McKesson updates also include portfolio actions and governance changes. Recent company materials document the completed divestiture of its Norwegian retail and distribution businesses, marking its exit from European operations, alongside recurring communications about earnings events, healthcare conferences, and leadership succession matters.
McKesson (MCK) and CD&R signed a definitive agreement to acquire Option Care Health (OPCH) for $32.05 per share in cash. The deal implies approximately $5.8 billion in enterprise value and a premium of approximately 37% to Option Care Health’s October 5, 2026 closing share price.
McKesson will invest approximately $1.4 billion for approximately 49% ownership; CD&R will hold approximately 51%. A framework allows McKesson’s future acquisition of CD&R’s interest, subject to specified conditions and regulatory approvals. Closing is expected in the first half of calendar 2027, subject to Option Care Health stockholder and required regulatory approvals. Option Care Health will remain separately managed and become privately held, with its shares leaving Nasdaq upon completion. It is withdrawing its previously disclosed financial guidance.
McKesson (MCK) signed an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032.
The extension covers distribution to mail order and specialty pharmacies, retail pharmacies, and distribution centers. The relationship has lasted more than 25 years. McKesson reaffirmed its fiscal 2027 adjusted earnings per share guidance of $44.20 to $45.00 and its long-term adjusted earnings per share growth rate of 13% to 16%. Further updates are scheduled for its second-quarter fiscal 2027 earnings call on November 4, 2026.
McKesson Corporation (MCK) will release its second quarter fiscal 2027 financial results after market close on Wednesday, November 4, 2026.
The company will host a live earnings conference call webcast for investors at 4:30 PM Eastern Time the same day. Live and archived audio of the webcast will be available through McKesson’s Investor Relations website.
McKesson (NYSE: MCK) signed a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services, for approximately $2.25 billion. Following closing, Precision Medicine Group will be reported within McKesson’s Oncology & Multispecialty segment.
According to McKesson, the acquisition is intended to enhance its clinical research and commercialization services, strengthen clinical trial execution, and broaden clinical service offerings. Precision Medicine Group supports next‑generation drug development with integrated, technology‑enabled services, including biomarker intelligence, lab services, a global clinical research organization, and market access and commercialization support. The transaction is subject to customary closing conditions, including regulatory clearances.
McKesson (NYSE: MCK) has released its fiscal 2027 first quarter financial results, which are available on the company’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.
The company will host a live earnings conference call and webcast for investors on Wednesday, August 5 at 4:30 PM ET. The audio webcast, earnings press release, financial tables, and slide presentation will be available live and archived on the Investor Relations site. Information on future investor events is available at investor.mckesson.com/events-and-presentations.
McKesson (NYSE:MCK) announced that its Board of Directors declared a regular quarterly dividend of $0.94 per share, representing a 15% increase from the prior quarter’s $0.82. The dividend is payable on October 1, 2026, to shareholders of record as of September 1, 2026. This marks McKesson’s tenth consecutive year of dividend growth, which the company links to business strength, disciplined capital allocation, and its focus on long-term shareholder value.
McKesson (NYSE:MCK) will release its first quarter fiscal 2027 financial results after market close on Wednesday, August 5, 2026. Following the release, the company will host a live earnings conference call at 4:30 PM Eastern Time, accessible via its Investor Relations website.
McKesson (NYSE:MCK) closed a strategic minority investment with Apollo Funds in its Medical-Surgical Solutions (MMS) business on June 1, 2026. Apollo Funds invested $1.25 billion in convertible preferred equity for an approximately 13% interest, implying a $13 billion enterprise value for MMS. McKesson maintains majority ownership, operating control, and financial consolidation.
McKesson (NYSE: MCK) released its fiscal 2026 fourth-quarter results and is hosting a live earnings webcast and conference call today, May 7 at 4:30 PM ET.
According to McKesson, the audio webcast will be available live and archived on the company’s Investor Relations site, along with the earnings release, financial tables, and slide presentation.
McKesson (NYSE:MCK) declared a regular quarterly dividend of $0.82 per share. The Board approved the dividend, which is payable on July 1, 2026 to shareholders of record as of June 1, 2026.